Opdivo first PD-1 inhibitor to demonstrate superior overall survival vs. standard of care
Bristol-Myers Squibb announced that Opdivo (nivolumab) is the first PD-1 inhibitor to demonstrate superior overall survival versus standard of care (docetaxel) in an open-label, randomized Phase III study (CheckMate -057) evaluating previously-treated patients with advanced, NSCLC. May 29, 2015